Latest News

Barcelona, Spain (UroToday.com) Platinum-based chemotherapy has been the standard first-line therapy for patients with metastatic urothelial cancer (mUC). Historically, response to standard of care second-line chemotherapy regimens is < 15%. Although immune checkpoint inhibitors (ICIs) now provide another option for patients with platinum-refractory mUC, response rates are similarly low, highlighting a critical need for novel therapeutic agents […]

Barcelona, Spain (UroToday.com) Cancer cells, including renal cell carcinoma cells, have long been known to preferentially utilize glycolysis rather than aerobic oxidative phosphorylation to produce intracellular ATP, a phenomenon known as the Warburg effect. In the relative absence of pyruvate created by the Warburg effect, cancer cells take up excess glutamine, which is converted to […]

Barcelona, Spain (UroToday.com) Professor Ignacio Durán provided a discussion of the recently presented ENTRATA and TROPHY-U-01 trials at the 2019 European Society for Medical Oncology annual meeting (ESMO) proffered paper session. ENTRATA was a randomized phase II study of telaglenastat + everolimus vs. placebo + everolimus in heavily pre-treated metastatic renal cell carcinoma (mRCC) patients, reporting a median […]

Barcelona, Spain (UroToday.com) Platinum-based chemotherapy remains the standard of care for patients with locally advanced or metastatic urothelial carcinoma. Despite the use of first-line PD-1/PD-1L inhibitors, 71–76% of patients who are cisplatin-ineligible do not respond to treatment. Enfortumab vedotin is an antibody-drug conjugate targeting Nectin-4, which is highly expressed in metastatic urothelial carcinoma. Enfortumab vedotin […]

Barcelona, Spain (UroToday.com) Altered glucose and glutamine metabolism is a hallmark of renal cell carcinoma (RCC). Abnormal glucose metabolism, known as the Warburg effect, deprives the citric acid cycle (TCA cycle) of critical metabolites. Cancer cells compensate for the Warburg effect by increasing glutamine metabolism to sustain the TCA cycle for growth and proliferation. Glutaminase […]

Barcelona, Spain (UroToday.com) Durvalumab is a PD-L1 inhibitor with efficacy in platinum-refractory advanced urothelial cancer and approved by the FDA after a reported response rate of 18%.1 FGFR targeted therapy (ie. erdafitinib) also has FDA approval in biomarker-selected patients with urothelial cancer based on a response rate of 40%.2 At the ESMO 2019 non-prostate cancer session, […]